Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Related Questions
Do you have different hotspot and heterogeneity goals for SBRT of ground glass lesions vs more solid adenocarcinoma NSCLC lesions?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
What target volumes and expansions would you use for neoadjuvant chemoradiotherapy to a large thymoma with the goal of shrinking the tumor to aid resectability?
How do you treat Stage IIIC T4N3 NSCLC?
Would a metal endobronchial stent within the treatment field change your radiation treatment plan for a thoracic malignancy?
What clinical and pathologic features do you use to discern whether >= 2 synchronous lung nodules, biopsy proven lung adenocarcinoma, are different primaries versus metastatic disease?
Given the results of LU002 presented at ASCO 2024, are there situations and/or patient subgroups who still derive benefit from local consolidative therapy for oligometastatic NSCLC?
Is there a chest wall constraint you typically use for 60 Gy in 15 fraction NSCLC treatment?
How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose-fractionation for locally advance NSCLC now getting RT alone?
What is your planning approach for SBRT when the tumor abuts the great vessels such as aortic arch or SVC?
